

Setting the pace ...

*Bringing Probabilities of
Success up with the right
platforms & technologies*



Cautionary statement regarding forward-looking statements

Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “goal”, “intend”, “look forward to”, “may”, “plan”, “potential”, “predict”, “project”, “should”, “will”, “would” and similar expressions. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements.

Welcome

The Management Team



Werner Lanthaler
CEO



Enno Spillner
CFO



Craig Johnstone
COO



Cord Dohrmann
CSO


Agenda

Highlights

Financial performance 2021

Scientific and operational performance 2021

Outlook and Guidance 2022



Strong overall performance and progress in all “lanes”

Highlights & lowlights 2021



Highlights


- Multiple new & extended integrated drug discovery & development alliances (**EVOiR&D**)
- Opening of J.POD® Redmond, WA (US); initiation of J.POD® Toulouse, France (EU) (**EVOaccess**)
- Very good progress in co-owned pipeline (**EVOroyalty**) (e.g. Bayer/B1 antagonist in DNP, BMS,...)
- Excellent progress in iPSC and protein degradation partnerships with Bristol Myers Squibb (BMS); Opt-in for EVT8683 & start of clinical development
- Multiple new EVT Innovate partnerships in e.g. heart failure, kidney disease, RNA-based drug discovery,...
- Accelerate innovative platforms & technologies – **EVOcells**, **EVOpanOmics**, **EVOpanHunter**, E.INVENT.AI, E.SOLVE, E.RNA etc...
- Launch of E.MPD, largest and highest quality molecular patient databases
- Launch of three new BRIDGES; PRROTECT, an initiative for pandemic preparedness;
- Steady progress within operational venturing strategy (e.g. Exscientia NASDAQ listing)
- NASDAQ listing with total gross proceeds of \$ 500 m

Lowlights

- Bayer discontinued development of eliapixant (BAY1817080) (after period-end)
- Increased costs for capacity expansion; increased costs for energy, ...

AP 2025 is fully in swing and accelerated by precision medicine

Action Plan 2025 in numbers




¹⁾ Including equity investments

²⁾ Does not include EVT equity investments

Platforms & technologies are high-tech driven & fully integrated

The drug discovery & development innovation hub – Capabilities & expertise overview

Industry needs




R&D efficiency platforms¹⁾



Precision medicine platforms





Just – Evotec Biologics¹⁾







Right modality drug design

Capabilities & Expertise (illustrative)




Faster and more learning curves illustrate technology leadership

“Evotec inside” (selected KPI’s 2020/21)

	<p>62 Patent applications</p>	<p>142 High-throughput screens</p>	<p>12 Pre-clinical development candidates (PDC)</p>	<p>24 INDiGO® programs</p>	<p>> 250 GMP API batches</p>
	<p>>10 Precision platforms</p>	<p>>200 bn Data points</p>	<p>>440 bn of iPSC-derived cells</p>	<p>>10,000 compounds assessed as protein degraders</p>	<p>>100 EVOPanHunter projects</p>
	<p>>15 Biologics projects</p>	<p>20 Months construction time</p>	<p>>40,000 samples in HT analytics and functional characterisation</p>	<p>>20 consecutive successful manufacturing runs</p>	<p>>90% J.POD® cGMP qualification activities completed</p>
	<p>>130 Co-owned pipeline assets</p>	<p>>90 Small molecules</p>	<p>>20 Biologics</p>	<p>>10 Cell & gene therapy</p>	<p>>10 Multiple modalities</p>

Platforms & technologies for more precision and efficiency

Evotec today – 15 Sites & more than 4,200 employees



USA

~500

- Branford
- Princeton
- Redmond, WA
- Seattle
- Watertown



Austria

~40

- Orth an der Donau

Italy

~800

- Verona (Campus Levi-Montalcini)

Germany

~1,050

- Hamburg (HQ) & Goettingen (Manfred Eigen Campus)
- Cologne
- Munich

UK

~950

- Abingdon (Dorothy Crowfoot Hodgkin Campus)
- Alderley Park

France


~900

- Lyon
- Toulouse (Campus Curie)



Attracting great talent – Growth enabled by culture & values

Growth of talent in 2021



- First time > 600 new employees hired in one year (net number)
- > 80% with at least one academic qualification; > 30% PhDs
- > 8 years drug discovery and development experience on average
- 54% female; senior executives 31% women
- 81 nationalities
- Average age of employees 38.5 years
- > 600 net new talents planned for 2022

Boost of expertise in high-impact areas

Recent key hires



- >30 years in pharmaceutical safety assessment
- GSK, Novo Nordisk, Pfizer; currently VP Regulatory Safety at AZ

Liz Mortimer-Cassen¹⁾
EVP Safety Assessment & Strategy



- >25 years biotechnology industry experience
- Amgen, BMS, Merck, ...

Valerie Alvarado
VP Capital Projects



- >20 years McKinsey & Company: Senior Partner & global co-lead R&D for pharma/biotech
- Broad exposure to cross-industry collaborative efforts

Matthias Evers²⁾
Chief Business Officer (BD, tech, strategy)



- > 20 years in biotechnology industry
- Amgen, Biocon, Baxter

Sundar Ramanan
SVP, Global Biotherapeutics Quality



- >20 years in life science industry in Europe, North America and Asia
- TVM Capital, GPC, MPM Capital, Aptorum ...

Mirko Scherer
Entrepreneur in Residence



- > 20 years in financial services including 14 years as a fund manager
- Polar Capital, Morgan Stanley

Daniel Mahoney
Entrepreneur in Residence



- >20 years experience mostly at Biologics CDMOs
- Catalent (Biologics & Cell Therapy divisions), PX'Therapeutics, Audival, A+A

Christelle Dagoneau
SVP BD biologics






- >20 years in life science industry, with expertise in cell therapy
- Achilles Therapeutics, GSK; Credit Suisse (biotech equity analyst)

Dara Henry
Entrepreneur in Residence

More than a decade of consecutive double digit annual growth

Results versus previous year and guidance

	FY 2020 results	FY 2021 results	Yoy growth reported / like-for-like ¹⁾	Guidance March 2021
Group revenues²⁾ (at constant fx-rates)	€ 500.9 m	€ 618.0 m (€ 627.2m)	23% / 27%	€ 550 – 570 m 
Unpartnered R&D³⁾	€ 46.4 m	€ 58.1 m	25% / 25%	€ 50 – 60 m 
Adjusted Group EBITDA⁴⁾ (at constant fx-rates)	€ 106.7 m	€ 107.3 m (€115.5 m)	1% / 18%	€ 105 – 120 m 

Significant growth step up and investments towards AP 2025

Guidance 2022

	Guidance 2022	YE 2021	Implied growth at midpoint
Group revenues (at constant fx-rates ¹⁾)	€ 700 – 720 m (€ 690 – 710 m)	€ 618.0 m	~15%
Unpartnered R&D²⁾	€ 70 – 80 m	€ 58.1 m	~30%
Adjusted EBITDA³⁾ (at constant fx-rates)	€ 105 – 120 m (€ 95 – 110 m)	€ 107.3 m	At least stable

Approx. € 300 m investment programme for enabling and supporting growth (e.g. capacity expansion, ...)


Agenda

Highlights

Financial performance 2021

Scientific and operational performance 2021

Outlook and Guidance 2022



Main KPIs underline positive development

Condensed income statement 2021 – Evotec SE and subsidiaries

in € m¹⁾

	2021	2020	Change
Revenues	618.0	500.9	23%
<i>Gross margin</i>	24.5%	25.1%	–
• R&D expenses	(72.2)	(63.9)	13%
• SG&A expenses	(105.4)	(77.2)	37%
• Impairment of intangible assets and goodwill	(0.7)	(3.2)	nm
• Other op. income (expenses), net	67.8	67.2	1%
Operating income	41.0	48.6	(16)%
Adjusted Group EBITDA²⁾	107.3	106.6	1%
Net income	215.5	6.3	>>>100%


- Revenue growth of 23% (excluding portfolio and fx effects: 27%) driven by all business areas
- Gross margin reflects ramp-up of J.POD® Redmond, WA (US)
- Increase in unpartnered R&D by 25% (€ 58.1 m vs. 2020: € 46.4 m) as planned
- Step-up of SG&A expenses mainly caused by headcounts (+26%), preparation for future growth, starting J.POD® Toulouse (F) and costs for public offering at NASDAQ (> € 3 m, of which € 1.7 m one-off)
- Adj. EBITDA like-for-like growth 18%
- **EVOequity**: Net income significantly higher due to fair value adjustment of Exscientia Ltd. US IPO

Revenue growth exceeding guidance – strong fundamentals

Revenues & Gross margin overview


Revenues (in € m)

- Base revenues
- Milestones, upfronts and licences



Gross margin (in %)

- Total Margin




- Group revenues +27% like-for-like
- Base business up 20% adjusted for Sanofi payment in Q1 2020
- Exceptionally strong milestone contribution of € 49.5 m, e.g. from BMS and Takeda collaborations
- Just – Evotec Biologics revenues of € 52.9 m (+35% vs. 2020: € 39.3 m)
- Gross margin development reflects
 - the anticipated fade-out of payments from Sanofi for the Toulouse site
 - the capacity build-up related to the launch of J.POD[®] Redmond, WA (US)
 - fx headwinds

Strong organic growth pointing to healthy demand

Revenue bridge 2020 – 2021 – Evotec SE and subsidiaries

in € m¹⁾



- 23% growth of Group revenues
- Organic growth of € 134.9 m translates into growth rate of 27%
- Reference point adjusted for Sanofi Toulouse payment of € (8.6 m) in Q1 2020
- fx headwinds: € (9.2) m or (1.8)%

Revenues up in both segments

Segment information 2021 – Evotec SE and subsidiaries

in € m¹⁾

	EVT Execute	EVT Innovate	Inter- segment elimination	Evotec Group
Revenues	610.2	147.0	(139.1)	618.0
<i>Gross margin</i>	20.9%	24.9%	–	24.5%
• R&D expenses	(2.9)	(81.9)	12.6.0	(72.2)
• SG&A expenses	(83.9)	(21.5)	–	(105.4)
• Impairment of intangible assets & goodwill	–	(0.7)	–	(0.7)
• Other op. income (expenses), net	22.4	45.4	–	67.8
Operating income	63.1	(22.1)	–	41.0
Adjusted Group EBITDA²⁾	124.8	(17.5)	–	107.3

- Total revenues show accelerated growth in fourth quarter in both segments
- EVT Execute total revenue growth up 20%; also third party revenue growth was 20%
- EVT Innovate revenues up 39%, due to strong milestone contribution and strong project business
- Adjusted EBITDA with further improvement in Q4 after strong Q3

Accelerating growth at year end

Condensed income statement Q4 2021 – Evotec SE and subsidiaries

in € m¹⁾


	Q4 2021	Q4 2020	Change
Revenues	187.1	140.5	33%
Gross margin	27.8%	26.0%	–
• R&D expenses	(18.7)	(17.9)	5%
• SG&A expenses	(34.4)	(19.1)	80%
• Impairment of intangible assets & goodwill	–	(3.2)	–
• Other op. income (expenses), net	16.0	16.9	(5)%
Operating income	14.9	13.3	13%
Adjusted Group EBITDA²⁾	37.2	29.7	25%
Net income	(31.5)	0.4	–

- Q4 revenue growth of 33%
- Strong milestone contribution leading to gross margin expansion, despite ramp-up of J.POD[®] Redmond, WA (US)
- SG&A expenses driven by planned investments to support the operational and financial growth (personnel costs, J.POD[®] Redmond, WA (US) and costs for public offering and dual listing at NASDAQ)
- EBITDA up 25%
- **EVOequity**: Net Income influenced by quarterly revaluation of Exscientia Ltd. and decreased share price (non-cash)

Exscientia IPO with very strong effect on net income (EVOequity)

Single steps from 2020 to 2021


in € m¹⁾



Strong cash position of > € 850m securing growth ambitions

Single steps from 2020 to 2021

in € m¹⁾



Expanded balance sheet as solid base for future growth

Balance sheet and liquidity – 31 December 2021 vs. 31 Dec. 2020 – Evotec SE & subsidiaries

Balance sheet total
in € m

1,462.9 **2,235.2**

Equity ratio
in %

49.4 **61.6**

Net Debt ratio (excl. IFRS 16)
x adjusted EBITDA¹⁾

(1.5) **(5.5)**

Liquidity position
in € m

481.9 **858.2**

- All relevant balance sheet metrics significantly strengthened due to profitable growth, public US offering and equity portfolio contribution
- Total assets, liabilities and equity increased by 53%
- Equity ratio step up by 12.2%-points
- Leverage ratio remains negative (net cash position) despite high capex for significant growth and **EVO** equity investments
- Robust liquidity position following the US listing


Agenda

Highlights

Financial performance 2021

Scientific and operational performance 2021

Outlook and Guidance 2022



Excellent position for continued growth


Major developments in 2021 (selection)

- **EVOiR&D**

- Multiple new and extended drug discovery and development (e.g. Abivax, EQRx, Bicycle Therapeutics, Evommune, Takeda,...)
- 91% repeat business, extensions, and growth within long-term partnerships
- > 800 partners across the industry (~13% up compared to 2020)
- Several new INDiGO agreements signed (e.g., with Oxford Cannabinoid Technologies or third INDiGO programme with Ildong)
- New ADME-collaboration with Amgen
- New collaboration with Novo Nordisk in gene therapy

- **EVOaccess: Just – Evotec Biologics**

- Several new collaborations (e.g. DoD expansion)
- J.POD® Redmond, WA, (US) opened in H2 2021
- J.POD® Toulouse, France (EU) initiated in 2021 and start construction in 2022



J.POD[®] – commercial biologics manufacturing stepping up

EVOaccess – Progress and status



J.POD[®] Redmond, WA (US) – Facility completed in just 19 months

- Grand opening in August 2021
- Production from a few kilograms to metric tons in the same facility
- Partner at every stage of the biologics value chain
- Start of operations fully on track e.g. US Department of Defense (DoD),...




J.POD[®] Toulouse, France (EU) – Project initiation

- On two hectares of land¹⁾ at Campus Curie design plan started
- Creates capacity for biological treatments in EU
- Significant support from French government, Occitanie region, Bpifrance, Haute-Garonne prefecture as well as Toulouse Métropole

Significant expansion of alliances is basis for long-term success


Attraction, Extension, Retention

Attraction




- Customer base more diversified; revenues have grown significantly

Extension



- Integrated drug discover & development offering yields increasing “share of wallet”
- Faster and better results versus in-house infrastructures


Structural Retention ≥90%



- Solid customer retention rates
- Strong basis for double-digit growth

Healthy demand points to continued strong growth

Orders versus Revenues – Evotec SE and subsidiaries



- Healthy demand leads to strongest order book in company's history
- Near-shoring and post-pandemic market shake-up result in favourable environment
- Growth perspectives to result in bold investment decisions and capacity expansion as well as structural adjustments to accelerated growth

Despite P2x3 set back - The iceberg keeps growing

In total >220 projects: ~180 in partnerships, >40 internal R&D projects

		Neuroscience & Pain				Oncology				Metabolic Diseases		Inflammation & Immunology ¹⁾			Virology	Anti-bacterial		Global Health		
Clinical	Ph3	Jingxin																SK bioscience		
	Ph2	P2X3 - CC	P2X3 - OAB	P2X3 - DNP	Bayer - B1	BI/Xynomic		Carrick				P2X3								
	Ph1	Centrexion				Exscientia		Carrick				Bayer								
Preclinical		Bayer	Bayer	BMS	Exscientia	Kazia		Carrick				Conba	Bayer	Topas				ND		
					Aeovian			Exscientia		EVT	ND	Fibrocor	Topas	Sanofi						
Discovery		ND	ND		Facio	Sanofi/Apeiron	ND		Autobahn		Eternigen		Exscientia	LAB150						
		ND	ND		Argobio	ND	ND	EVT	Immunitas		NephThera		Topas	LAB282				ND		
		ND	EVT	EVT	LAB282	ND	ND	EVT	Exscientia	Breakpoint	ND	LAB282		Celmatix	Fibrocor		ND	Forge	ND	
		ND	ND			EVT			Autobahn	DarkBlue	QRbeta	EVT	ND	ND	Celmatix					
		ND	ND			EVT			Breakpoint	LAB282	ND	EVT	NephThera	ND	ND	Blacksmith				
		ND	ND		LAB282	EVT	EVT	Carrick	Blacksmith	Danube Labs	EVT	EVT	EVT	ND	Autobahn	Fibrocor	LAB282	Myxob	Forge	ND
		ND			Autobahn	ND	EVT/MF		Immunitas		ND	ND			Celmatix		ND			
		ND	ND		Cajal Neuro	ND	EVT/MF	EVT	Quantro	BELAB1407	ND	ND	EVT		CureXsys		ND			
		ND	ND	EVT	Facio	ND	EVT/Indiv	EVT	Ananke	BELAB2122	ND	EVT	EVT		Exscientia		ND	ND	ND	
		ND	ND	EVT	Exscientia	ND	EVT	EVT	Autobahn	LAB282	ND	EVT	LAB282	ND	Fibrocor		ND	ND	ND	
		ND	ND	EVT	CureXsys	LAB282	ND	EVT	Exscientia	LAB150	ND	EVT	LAB150	ND	LAB150		ND	Exscientia	Forge	ND
		ND	ND	EVT	EVT	LAB150	ND	ND	EVT	OxVax	Argobio	ND	EVT N=4	NephThera	EVT	LAB282	ND	LAB282	ND	Exscientia

■ Partnered Pipeline
 ■ Unpartnered Pipeline
 ■ Equity Pipeline
 ■ Bridges Pipeline
 + Positive clinical trial results
 € Key milestone achieved
 ▶ Initiation of clinical trial
 Development progress and/or new project
 ↑ Phase change
 🤝 New partnership

¹⁾ Also includes Women's Health, Respiratory projects
 The Equity Pipeline does not contain programs from EVT/partners that are not publically disclosed

“Evotec Inside”

Steady stream of high-value catalysts


Selected pipeline events within next 12 – 24 months




- Phase III & registration (CHN) JingXin in insomnia (EVT201)
- Phase II data with Bayer in DNP (BAY2395840)
- Phase II initiation with Bayer in Gynaecology (BAY2395840)
- Phase I data in Chikungunya virus (EVT894)
- Phase I data with BMS in CNS (EVT8683)
- Phase I data with Exscientia in Oncology (EXS21546)
- Phase I data with Kazia in Oncology (EVT801)
- Phase I initiation in Covid-19 / HBV (EVT075)
- Phase I Initiation with Bayer in Kidney diseases
- Phase I Initiation with Kidney diseases with other partners
- Phase I initiation with BMS in CNS
- Phase I Initiation with BMS in Oncology
- Multiple co-owned equity companies (not outlined here) will progress in clinic (e.g. Topas, Forge, Carrick, Fibrocor, ...)

	Molecule	Therapeutic Area/Indication	Partner	Discovery	Pre-clinical	Phase I	Phase II	Phase III
Clinical	EVT201	Insomnia (GABA-A)	京新药业					
	Not Disclosed	Infectious Disease (Antibody)	SK bioscience					
	BAY2395840	Diabetic Neuropathic Pain (B1)						
	CT7001	Oncology (CDK7)	Carrick					
	XP-105	Oncology (mTORC1/2)	XYNOMIC					
	EVT401	Immunology & Inflammation (P2X7)	康源集团 CONSA GROUP					
	BAY2328065	Gynaecology						
	EXS21546	Oncology (various programmes)	Exscientia					
	CNTX 6016	Pain (CB2)	CENTREXION					
	EVT894	Chikungunya (Antibody)	SANOFI					
	Not Disclosed	Neuroscience & Pain	n.a.					
	Not Disclosed	Neuroscience & Pain	n.a.					
	EVT801	Oncology (VEGFR3)	KAZIA					
	EVT8683	Neurodegeneration (eIF2b activator)	Bristol Myers Squibb*					
	TPM203	Pemphigus Vulgaris (ND)	Topas Therapeutics					
CT7001	Oncology (CDK7)	Carrick						
CT7001	Oncology (CDK7)	Carrick						
Pre-clinical	APN411	Oncology – Immunotherapy	SANOFI APEIRON					
	GLPGxxxx	Fibrosis (not disclosed)	galapagos					
	BAYxxxx	Nephrology (not disclosed)						
	QRB001	Metabolic – Diabetes (not disclosed)	QRBeta					
	EVT075	Covid-19 / HBV	n.a.					
	Not disclosed	Various programmes	Bristol Myers Squibb*					
	EVTxxxx	CNS, Metabolic, Pain, ...	>10 further programmes					
Discovery	Multiple programmes across nephrology, oncology, immunology among other therapeutic areas							

Precision medicine is the only path to improved medicine


Leading AI/ML driven drug discovery & development platforms



	<ul style="list-style-type: none"> • Transcriptomics and proteomics data at industrial scale • Multiple patient-derived data bases, e.g. CKD database (>10,000 patients; >600 billion data points)
	<ul style="list-style-type: none"> • User friendly AI/ML driven multi-omics analysis platform • Exceeding industry standards in predicting drug safety (e.g.: liver injury 86% vs. 70%)
	<ul style="list-style-type: none"> • One of the largest and most sophisticated iPSC platforms for drug discovery in industry • First iPSC-derived drug candidate in clinic, large pipeline evolving in drug discovery and cell therapy


Deep understanding of biology for precision medicine

The Evotec Molecular Patient Database (E.MPD)



E.MPD core component of alliances in CKD

Example: CKD strategic drug discovery deals



From Target identification & validation, via biomarker identification, to patient stratification


Agenda

Highlights

Financial performance 2021


Scientific and operational performance 2021

Outlook and Guidance 2022



EVO equity accelerates co-owning strategy

Operational VC model – diversified portfolio with multiple shots on goal



Attractive portfolio with significant upside

At Equity Holding (≥20%) or Significant influence



Minority Shareholdings (<20%)




BRIDGES



Keeping the promise

ESG & Sustainability – Measures taken in 2021



Responsible use of resources

- Sourcing of 100% renewable energy since January 2021 at all German sites
- Decision to replace heating system in building B95 in Abingdon (est. CO₂e savings of ~800t /yr)
- **EVO**earth week to raise overall awareness towards the protection of environment
- Software¹⁾ implementation for systematic emission data collection as basis to set SBTi targets

ESG topics part of our DNA

- Group-wide inclusion of ESG topics in personal 2021 targets of all employees
- Definition of responsibilities for delivering expanded set of sustainability KPIs
- Group-wide appreciation & celebration of diversity weeks in May and pride month in June
- DEI – Diversity, Equity & Inclusion: Conception of global diversity strategy

Intensified stakeholder dialogue

- MSCI ESG rating up from BBB to A as of January 2021
- ISS ESG rating up from C- to C as of May 2021
- EcoVadis rank up from 48 pts to 53 pts in Q4
- Decision to report in reference to GRI standards for FY 2021 as SASB and TCFD are too “E”-focused

Strong news flow to be continued ...

Selected latest news in Q1 2022

evotec #RESEARCHNEVERSTOPS

NEWS RELEASE, 21 MARCH 2022

EVOTEC RECEIVES € 3 M MILESTONE PAYMENT FOR BAYER STARTING PHASE II CLINICAL DEVELOPMENT OF DNP PROGRAMME

- ▶ FIRST DOSING OF A STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 3 M TO EVOTEC
- ▶ PHASE II CLINICAL TRIAL INITIATED BY EVOTEC'S PARTNER BAYER TO EVALUATE BAY 2395840 AS A POTENTIAL TREATMENT FOR DIABETIC NEUROPATHIC PAIN

Hamburg, Germany, 21 March 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company received a € 3 m milestone payment from Bayer AG as a result of another promising small molecule from the Evotec-Bayer multi-target research alliance advancing into Phase II clinical development as a potential treatment for diabetic neuropathic pain ("DNP").

DNP is a common chronic condition associated with nerve damage caused by high blood sugar levels in diabetic patients. DNP may be triggered through the slightest touch upon which the body sends unprompted pain signals to the brain. Thus, DNP can drastically impair the quality of life for people living with this condition.

BAY 2395840 is an investigational oral antagonist of the bradykinin receptor B₁ ("BDKRB₁"), which is known to play a role in pain perception.

Bayer has initiated a Phase II clinical trial to evaluate the safety and efficacy of BAY 2395840 in patients with DNP compared to placebo. The phase II study is anticipated to run until the end of 2022.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are excited that Bayer is moving ahead with the Phase II clinical development of an asset from our multi-target research alliance. The role of the bradykinin receptor B₁ for pain reception is well documented. We are confident that the highly selective BDKRB₁ antagonist BAY 2395840 stands a good chance to provide a new, urgently needed therapeutic option for DNP patients."

evotec #RESEARCHNEVERSTOPS

RELEASE, 18 JANUARY 2022

EVOTEC AND LILLY ENTER INTO DRUG DISCOVERY COLLABORATION IN METABOLIC DISEASES

- ▶ COLLABORATION LEVERAGES EVOTEC'S BROAD METABOLIC EXPERTISE AND UNIQUE KIDNEY DISEASE PATIENT DATABASE AS WELL AS INTEGRATED DATA-DRIVEN DRUG DISCOVERY AND DEVELOPMENT PLATFORMS
- ▶ LILLY HAS THE RIGHT TO SELECT UP TO FIVE PROGRAMMES

Hamburg, Germany, 18 January 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered into a drug discovery collaboration with Eli Lilly and Company ("Lilly") in the field of metabolic diseases with a focus on kidney diseases and diabetes.

The collaboration leverages Evotec's extensive experience and track record of delivering in the field of metabolic diseases, as well as its unique and extensive kidney disease patient database, to identify and validate promising novel targets for therapeutic intervention. Evotec will be responsible for the discovery of potential drug candidates for the treatment of diabetes and chronic kidney diseases from targets identified by Lilly or by Evotec. Lilly reserves the right to select up to five programmes developed within this partnership and to continue with any subsequent development, clinical validation and commercialisation.

The collaboration initially runs for a term of three years. In addition to an undisclosed upfront payment, Evotec will be eligible to receive success-based discovery development, regulatory and commercial milestone payments of up to US\$ 180 m per programme, as well as tiered royalties on net sales of any products resulting from the collaboration, for a potential overall value up to US\$ 1 bn.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are excited to enter into this research partnership with Lilly. Over a period of several years, Evotec has systematically built a proprietary patient database by conducting multi-omics analyses of biospecimens from patient biobanks covering metabolic and kidney diseases. Evotec's patient-derived molecular data in combination with our

evotec #RESEARCHNEVERSTOPS

RELEASE, 25 JANUARY 2022

EVOTEC ENTERS IPSC-BASED DRUG DISCOVERY PARTNERSHIP WITH BOEHRINGER INGELHEIM IN OPHTHALMOLOGY

- ▶ PARTNERSHIP LEVERAGES EVOTEC'S HUMAN IPSC-BASED PHENOTYPIC SCREENING AND PANOMICS PLATFORMS
- ▶ AIM IS TO IDENTIFY AND VALIDATE PROMISING TARGETS AND NEW APPROACHES FOR THERAPEUTIC INTERVENTIONS

Hamburg, Germany, 25 January 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered a target and drug discovery partnership with Boehringer Ingelheim, focusing on induced pluripotent stem cell ("iPSC")-based disease modelling for ophthalmologic disorders. Millions of people are affected by vision-related diseases worldwide, and there is a high unmet need for novel therapeutic solutions.

Through phenotypic screening of human iPSC-derived cells, supported by Evotec's PanOmics platform, Evotec will identify small molecules able to modulate disease phenotypes, and then validate the underlying promising targets for potential therapeutic interventions. Boehringer Ingelheim will then continue with the discovery and development of potential therapeutic candidates. Besides an undisclosed upfront and FTE-based research payment, Evotec will continue to benefit from the successful further development of the candidates in the form of milestones and layered royalties.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are excited to utilise our unique iPSC- and PanOmics-based approaches to ophthalmologic diseases in this new partnership with Boehringer Ingelheim. Phenotypic screening approaches have a long history of delivering highly effective drugs based on novel molecular mechanisms. Phenotypic screens based on human iPSC-derived disease models combined with our unbiased PanOmics readouts are more likely to deliver disease relevant drugs than any other cell-based screening approach."

evotec #RESEARCHNEVERSTOPS

RELEASE, 11 JANUARY 2022

EVOTEC EXPANDS NEUROSCIENCE COLLABORATION WITH BRISTOL MYERS SQUIBB TO INCLUDE NEW TARGETED PROTEIN DEGRADATION APPROACH

- ▶ EXPANSION LEVERAGES A PROPRIETARY EVOTEC PLATFORM IN THE FIELD OF TARGETED PROTEIN DEGRADATION TO TACKLE SELECTED TARGETS WITH RELEVANCE FOR A RANGE OF NEURODEGENERATIVE CONDITIONS
- ▶ EVOTEC RECEIVES PAYMENTS OF IN TOTAL US\$ 15 M FROM BRISTOL MYERS SQUIBB

Hamburg, Germany, 11 January 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has expanded its neurodegeneration collaboration with Bristol Myers Squibb (NYSE: BMY) with the initiation of discovery and development efforts regarding a new strategy to tackle neurodegenerative diseases including Alzheimer's through a novel approach to targeted protein degradation. Evotec receives payments totalling US\$ 15 m from Bristol Myers Squibb.

Under the expansion, Bristol Myers Squibb increases its access to a novel targeted protein degradation approach. The focus will be on selected targets that are relevant to a range of neurodegenerative conditions.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "Our collaboration with Bristol Myers Squibb in the field of neurodegenerative disease continues to be highly productive. Many neurodegenerative diseases are driven by disease-causing proteins which have proven to be elusive to traditional drug discovery approaches. We are committed to continuously explore novel drug targeting mechanisms and modalities and are delighted to have a strong partner with BMS in this endeavour."

The neurodegeneration collaboration between Evotec and Bristol Myers Squibb was initiated in December 2016 with the goal of identifying disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients' symptoms despite a huge unmet medical

evotec #RESEARCHNEVERSTOPS

RELEASE, 03 JANUARY 2022

EVOTEC RECEIVES € 7.5 M GRANT FOR DEVELOPMENT OF COVID-19 THERAPEUTIC

- ▶ EVOTEC RECEIVES A € 7.5 M GRANT FROM THE GERMAN FEDERAL MINISTRY OF EDUCATION AND RESEARCH ("BMBF") FOR THE DEVELOPMENT OF A THERAPEUTIC AGAINST COVID-19
- ▶ EVOTEC IS DEVELOPING A HIGHLY POTENT IMMUNOMODULATORY MOLECULE THAT HOLDS THE POTENTIAL TO AMPLIFY THE IMMUNE RESPONSE AND REDUCE THE RISK OF DIFFICULT DISEASE PROGRESSION AND HOSPITALISATION

Hamburg, Germany, 03 January 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has been selected by the German Federal Ministry of Education and Research ("BMBF") to receive a grant for the development of EVT075, a potential first-in-class immunomodulatory therapy against COVID-19. Evotec is one of three companies receiving a highly competitive grant as part of a new initiative by the BMBF to support the clinical development of novel therapeutic candidates against COVID-19.

Under the € 7.5 m grant, Evotec will use clinical material manufactured within its Just – Evotec Biologics manufacturing platform to initiate the clinical development of a potentially highly potent immunomodulatory molecule. Utilising the assays developed as part of the Company's global Pandemic Preparedness and Rapid Response initiative "PRROTECT", Evotec has demonstrated potent activity of the molecule in pre-clinical *in-vitro* studies. The molecule has shown great potential to produce a powerful antiviral response against infections with SARS-CoV-2 ("coronavirus"). By amplifying the immune response against coronavirus infections, the molecule can potentially reduce the viral load. Thus, the early administration of this biologic may significantly lower the risk of a severe progression of COVID-19 that requires hospitalisation of patients.

Evotec intends to use the grant to initiate clinical studies assessing the safety and efficacy of the compound and to determine the optimal dose-range in healthy volunteers as well as COVID-19 patients.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "As we enter the third year of the COVID-19 pandemic, it has become apparent that

Setting the pace to accelerate growth along Action Plan 2025

Selected key events to watch 2022



R&D efficiency platforms

- Undisrupted growth in line with AP 2025; Continued double digit growth of base business (**EVOiR&D**)
- Significant capacity and value chain expansion for all modalities and sites

Precision medicine platforms


- New strategic partnerships, important milestones, and expansions of co-owned alliances; Multiple clinical trial initiations and progression of co-owned pipeline; (**EVOroyalty**)
- Spin-Offs and investments along Building Blocks of AP 2025 (**EVOequity**)

Just – Evotec Biologics


- Start of production J.POD[®] Redmond, WA (US); Start of construction J.POD[®] Toulouse, France (EU)
- Multiple new partnerships (**EVOaccess**)

Our mid-term aspirations are “... just the beginning”

2020-2025e Key Performance Indicator goals



Revenues
in € m



Adjusted EBITDA¹⁾
in € m



Unpartnered R&D
in € m



Co-owned projects²⁾



¹⁾ before significant royalties

²⁾ incl. Equity participations

Upcoming important dates


Financial calendar 2022

Quarterly Statement Q1 2022	11 May 2022
Virtual Annual General Meeting 2022	22 June 2022
Half-year 2022 Interim Report	11 August 2022
Quarterly Statement 9M 2022	09 November 2022



Full annual report and sustainability report 2021 available for download on 26 April 2022

QUESTIONS
AND ANSWERS



Appendix

Profit & Loss Statement

31 December 2021 vs. 31 Dec. 2020 – Evotec SE consolidated

<i>in k€ except share and per share data</i>	Year ended 31 December 2021	Year ended 31 December 2020
Revenues	618 034	500 924
Costs of revenue	(466 491)	(375 181)
Gross profit	151 543	125 743
Operating income and (expenses)		
Research and development expenses	(72 200)	(63 945)
Selling, general and administrative expenses	(105 445)	(77 205)
Impairment of intangible assets	(683)	(3 244)
Impairment of goodwill	–	–
Other operating income	73 472	72 175
Other operating expenses	(5 691)	(4 968)
Total operating income and (expenses)	(110 547)	(77 187)
Operating income	40 996	48 556
Total non-operating income (expense)	195 984	(22 716)
Total taxes	(21 470)	(19 562)
Net income	215 510	6 278
thereof attributable to:		
Shareholders of Evotec SE	215 510	6 278
Non-controlling interest	–	–
Weighted average shares outstanding	166 405 926	153 752 241
Net income per share (basic)	1,30	0,04
Net income per share (diluted)	1,30	0,04

Balance Sheet

31 December 2021 vs. 31 Dec. 2020 – Evotec SE consolidated

<i>in k€</i>	as of 31 December 2021	as of 31 December 2020
ASSETS		
Current assets		
Cash and cash equivalents	699 326	422 580
Investments	158 908	59 350
Trade accounts receivables	132 078	79 005
Prepaid expenses and other current assets	39 895	30 404
Other	70 733	67 505
Total current assets	1 100 940	658 844
Non-current assets		
Long-term investments	268 793	19 289
Long-term investments accounted for using the equity method	13 068	39 710
Property, plant and equipment	484 597	337 297
Intangible assets, excluding goodwill	30 851	98 036
Goodwill	257 569	247 370
Other	79 343	61 791
Total non-current assets	1 134 221	803 493
Total assets	2 235 161	1 462 337
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities		
Current loan liabilities	36 136	15 392
Current portion of lease obligations	14 473	14 616
Trade accounts payable	72 598	42 549
Provisions	39 260	41 848
Contract liabilities	112 061	66 477
Other	49 988	27 577
Total current liabilities	324 516	208 459
Non-current liabilities:		
Non-current loan liabilities	326 344	331 019
Long-term lease obligations	135 964	130 938
Contract liabilities	33 476	22 437
Other	37 176	45 028
Total non-current liabilities	532 960	529 422
Equity attributable to shareholders of Evotec SE	1 377 685	724 456
Non-controlling interest	-	-
Total stockholders' equity	1 377 685	724 456
Total liabilities and stockholders' equity	2 235 161	1 462 337

Cash Flow Statement

31 December 2021 vs. 31 Dec. 2020 – Evotec SE consolidated

<i>in k€</i>	2021	2020
Cash flows from operating activities		
Net income	215 510	6 278
Depreciation of property, plant and equipment	55 596	42 122
Amortisation of intangible assets	12 012	13 936
Depreciation of current assets	2 791	160
Impairment of intangible assets	683	3 244
Fair value adjustments on long-term investments	(223 791)	(1 500)
Accounts receivables	(48 032)	(4 178)
Inventories	(11 653)	(3 631)
Accounts payable	31 341	2 165
Contract liabilities and deferred income	63 083	(14 618)
Other	24 697	743
Net cash provided by operating activities	122 237	44 721
Cash flows from investing activities		
Purchase of current investments	(123 696)	(70 932)
Purchase of property, plant and equipment	(118 943)	(99 072)
Other	(1 216)	14 915
Net cash used in investing activities	(243 855)	(155 089)
Net cash provided by (used in) financing activities	398 430	246 409
Net increase (decrease) in cash and cash equivalents	276 812	136 041
Exchange rate difference	(66)	9 505
Cash and cash equivalents at beginning of year	422 580	277 034
Cash and cash equivalents at end of the period	699 326	422 580
Supplemental schedule of non-cash activities		
Additions to leases	14 292	68 044



#RESEARCHNEVERSTOPS

Your contact:

Volker Braun
SVP Head of Global Investor Relations & ESG

+49.(0).40.560 81-775
+49.(0).151.1950 4058
volker.braun@evotec.com
